We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Protein Biomarker Panel Enables Early Detection of Cancer

By LabMedica International staff writers
Posted on 02 Sep 2019
Analysis of biomarker expression data from serum obtained from ovarian cancer patients has enabled development of an early detection tool for epithelial ovarian cancer (EOC).

Five-year survival is nearly 90% if EOC is diagnosed at stage one, while this drops to only 22% if the disease is diagnosed at stage three or four. More...
Ovarian cancer is the sixth most common cancer among women in the United Kingdom, causing more than 4000 deaths in 2016.

In searching for biomarkers to facilitate early detection of EOC, investigators at Queens University Belfast (United Kingdom) and collaborators in the United Kingdom, Australia, and Italy analyzed samples from 49 EOC cases (19 Type I and 30 Type II) and 31 controls who were participants in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS), representing 482 serial samples spanning seven years pre-diagnosis. A logit model was trained by analysis of dysregulation of expression data of four putative biomarkers, (CA125, phosphatidylcholine-sterol acyltransferase, vitamin K-dependent protein Z, and C-reactive protein).

The analysis conducted in the current study presented a screening tool based on the dysregulation of the four biomarkers compared to a pre-disease baseline established for each individual patient. The tool’s utility was demonstrated in a simulated annual screening programme providing the basis to consider, with the addition of further validation studies, how this may translate to a clinically viable screening program.

Senior author Dr. Robert (Bobby) Graham, reader in the school of biological sciences at Queen’s University Belfast, said, “Firstly, we discovered that the presence of the biomarker panel will enable us to detect EOC. We then developed a screening test to detect this biomarker panel, making this a relatively simple diagnostic test. The algorithm designed will screen the blood sample and flag any abnormal levels of the proteins associated with the cancer. The screening test identifies ovarian cancer up to two years before the current tests allow. The results of this study are encouraging, however, we now want to focus on testing it in a wider sample set so that we can use the data to advocate for an ovarian cancer screening program.”

The study was published in the August 7, 2019, online edition of the British Journal of Cancer.

Related Links:
Queens University Belfast


Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.